Second Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>SS</div>
EYES -- USA Stock  

USD 1.89  0.05  2.58%

The next earnings report is expected on the 18th of March 2021. The stock is currently experiencing an active upward rally. As many retail investors are getting excited about healthcare space, it is fair to sum up Second Sight Medical outlook under the latest economic conditions. Should we be more optimistic in anticipation of a recovery?
Published over two weeks ago
View all stories for Second Sight | View All Stories
Our latest take on Second (NASDAQ:EYES) analyst consensus
Second Sight is OVERVALUED at 1.98 per share with modest projections ahead. We provide advice to complement the current expert consensus on Second Sight. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Second Sight? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

How important is Second Sight's Liquidity

Second Sight financial leverage refers to using borrowed capital as a funding source to finance Second Sight Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Second Sight financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Second Sight's total debt and its cash.

How Second utilizes its cash?

To perform a cash flow analysis of Second Sight, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Second Sight is receiving and how much cash it distributes out in a given period. The Second Sight cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Second Sight Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Second Sight reported last year Net Cash Flow from Operations of (24.87 Million)

Is Second a risky opportunity?

Let's check the volatility. Second is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Second (NASDAQ:EYES) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. buying a share of a Second Sight stock makes you a part-owner of that company.

Are Second Sight technical ratios showing a reversion?

The value at risk is down to -11.01 as of today. Second Sight Medical is displaying above-average volatility over the selected time horizon. Investors should scrutinize Second Sight Medical independently to ensure intended market timing strategies are aligned with expectations about Second Sight volatility.

Our Final Take On Second Sight

While some other companies within the medical devices industry are still a little expensive, even after the recent corrections, Second Sight may offer a potential longer-term growth to retail investors. To summarize, as of the 4th of January 2021, our latest 30 days 'Buy-Sell' recommendation on the enterprise is Cautious Hold. We believe Second Sight is overvalued with high odds of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Second Sight Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com